CA153在乳腺癌免疫治疗中的作用

doi:10.11904/j.issn.1002-3070.2019.06.018

Abstract

Abstract: Breast cancer is a common malignant tumor in women,and immunotherapy is one of the treatments with a good clinical prognosis.CA153 can activate immune response as a specific antigen in breast cancer immune response;participate in T cell activation;target binding peptide vaccine;enhance immune response;induce dendritic cell maturation,and eliminate cancer cells in vivo.Therefore,CA153 plays an important role in the immune response and treatment of breast cancer,and can be used as a new target for breast cancer immunotherapy.

Key words: CA153, Breast cancer, Immunotherapy, Target

CLC Number:

R730.4

CAO Difei, HUANG Guoqing, XUE Jiaying, WU Qiong, WANG Lei, LI Yao. The role of CA153 in breast cancer immunotherapy[J]. Journal of Practical Oncology, 2019, 33(6): 566-569.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2019.06.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2019/V33/I6/566

References

1 钱六七,刘芊,刘毅,等.循环肿瘤细胞在转移性乳腺癌中的表达及其与多种血清肿瘤标志物的关系[J].实用肿瘤学杂志,2012,26(3):220-224.
2 Van Dalen A,Favier J,Baumgartner L,et al.Serum levels of CA 125 and TPS during treatment of ovarian cancer[J].Anticancer Res,2000,20(6):5107-5108.
3 Pan D,Chen J,Feng C,et al.Preferential localization of MUC1 glycoproteinin exosomes secreted by non-small cell lung carcinoma cells[J].Int J Mol Sci,2019,14(2):323.
4 Li X,Bleumink-Pluym NMC,Luijkx YMCA,et al.MUC1 is a receptor for the Salmonella SiiE adhesin that enables apical invasion into enterocytes[J].PLoS Pathog,2019,15(2):e1007566.
5 Apostolopoulos V,Stojanovska L,Gargosky SE,et al.MUC1(CD227):a multi-tasked molecule:CMLS[J].Cell Mol Life Sci,2015,72(23):4475-4500.
6 Song W,Delyria ES,Chen J,et al.MUC1 glycopeptide epitopes predictedby computational glycomics[J].Int J Oncol,2012,41(6):1977-1984.
7 Nath S,Mukherjee P.MUC1:a multifaceted oncoprotein with a key role in cancer progression[J].Trends Mol Med,2014,20(6):332-342.
8 Dhar P,Ng GZ,Dunne EM,et al.Mucin 1 protects against severe streptococcus pneumoniae infection[J].Virulence,2017,8(8):1631-1642.
9 Jing X,Liang H,Hao C,et al.Overexpression of MUC1 predicts poor prognosis in patients with breast cancer[J].Oncol Rep,2019,41(2):801-810.
10 Posey A,Schwab R,Boesteanu A,et al.Engineered CAR T cells targeting the cancer-associated tnglycoform of the membrane mucin MUC1 control ade-nocarcinoma[J].Immunity,2016,44(6):1444-1454.
11 Hillman GG,Reich LA,Rothstein SE,et al.Radiotherapy and MVA-MUC1-IL-2vaccine act synergistically for inducing specific immunity to MUC-1 tumorantigen[J].J Immunother Cancer,2017,5:4.
12 Takeshima T,Chamoto K,Wakita D,et al.Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL:its potentiation by combination with Th1 cell therapy[J].Cancer Res,2010,70(7):2697-2706.
13 Kimura T,McKolanis JR,Dzubinski LA,et al.MUC1 vaccine for individual with advanced adenoma of the colon:a cancer immunoprevention feasibility study[J].Cancer Prev Res,2013,6(1):18-26.
14 Hanafi-Bojd MY,Moosavian Kalat SA,Taghdisi SM,et al.MUC1 aptamer conjugated mesoporous silica nanoparticles effectively target breast cancer cells[J].Drug Dev Ind Pharm,2018,44(1):13-18.
15 Limacher JM,Quoix E.TG4010:A therapeutic vaccine against MUC1 expressing tumors[J].Oncoimmunology,2012,1(5):791-792.
16 Taylor-Papadimitriou J,Burchell JM,Graham R,et al.Latest developments in MUC1 immunotherapy[J].Biochem Soc T,2018,46(3):659-668.
17 Ahmad R,Alam M,Rajabi H,et al.The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function[J].JBC,2012,287(25):20866-20875.
18 Nabavinia MS,Gholoobi A,Charbgoo F,et al.Anti-MUC1 aptamer:a potential opportunity for cancer treatment[J].Med Res Rev,2017,37(6):1518-1539.
19 Zhou R,Yazdanifar M,Roy LD,et al.CAR T cells targeting the tumor MUC1 glycoprotein reduce triple negative Breast Cancer growth[J].Front Immunol,2019,24(10):1149.
20 Madsen CB,Wandal HH,Pedersen AE.Potential for novel MUC1 glycopeptide specific antibody in passive cancer immunotherapy[J].Immunopharmacol Immunotoxicol,2013,35(6):649-652.
21 Zhou D,Xu L,Huang W,et al.Epitopes of MUC1 tandem repeats in cancer as revealed by antibody crystallography:toward glycopeptide signature-guided therapy[J].Molecules,2018,23(6):1326.
22 Wang Y,Liu C,Xia Q,et al.Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs[J].Oncol Rep,2014,31(3):1437-1444.
23 Movahedin M,Brooks TM,Supekar NT,et al.Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen[J].Glycobiology,2017,27(7):677-687.
24 Lakshminarayanan V,Supekar NT,Wei J,et al.MUC1 vaccines comprised of glycosylated or non-glycosylated peptides or tumor-derived MUC1 can circumvent immunoediting to control tumor growth in MUC1 transgenic mice[J].PLoS One,2016,11(1):e0145920.
25 Vasir B,Zarwan C,Ahmad R,et al.Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1,CEA,and a triad of costimulatory molecules(rF-PANVAC)[J].J Immunother,2012,35(7):555-569.
26 Schettini J,Kidiyoor A,Besmer DM,et al.Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity[J].Cancer Immunology Immunotherapy,2012,61(11):2055-2065.
27 Alves LN,Missailidis S,Lage CAS,et al.Anti-MUC1 aptamer as carrier tool of the potential radiosensitizer 10 phenanthroline in MCF-7 Breast Cancer cells[J].Anticancer Res,2019,39(4):1859-1867.
28 Pillai K,Pourgholami MH,Chua TC,et al.MUC1 as a potential target in anticancer therapies[J].Am J Clin Oncol,2015,38:108-118.

[1]	SHEN Yizhe, GUO Baoliang. Progress in local treatment of newly diagnosed stage IV breast cancer [J]. Journal of Practical Oncology, 2019, 33(6): 575-578.
[2]	SHI Manru, E Mingyan. Effect of delayed radiotherapy on the prognosis of patients with different molecular subtypes of breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 431-435.
[3]	HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway [J]. Journal of Practical Oncology, 2019, 33(5): 451-455.
[4]	LI Lei, ZHANG Qingyuan. Clinical progress of anti-tumor vascular therapy for breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 461-465.
[5]	WANG Yu, QIAO Juanjuan, ZHANG Lei, LIU Siwei, YANG Shucai. The role of steroid hormones in breast cancer and its effect on cancer stem cells [J]. Journal of Practical Oncology, 2019, 33(5): 466-470.
[6]	LIU Eryu, YANG Hao, LIANG Guohua, ZHAO Yanfang, ZHAO Wenhui. Action for CDK4/6 inhibitors combined with mTOR inhibitors in breast cancer and its mechanism [J]. Journal of Practical Oncology, 2019, 33(5): 476-480.
[7]	AN Weiwei, TANG Yali, ZHAO Lianhua, YANG Yue, WANG Xinling. Polyphenylene-polysaccharide complex from pinus koraiensis extract induces apoptosis in human breast cancer MCF-7 cells [J]. Journal of Practical Oncology, 2019, 33(4): 289-293.
[8]	HU Lin, SHEN Jia. Growth differentiation factor 15 plays a role in predicting and monitoring the cardiotoxicity of epirubicin/cyclophosphamide-docetaxel-trastuzumab in the treatment of patients with HER-2 positive breast cancer [J]. Journal of Practical Oncology, 2019, 33(4): 340-345.
[9]	MA Yan, HE Hong, WANG Sainan. Clinical study of docetaxel in the treatment of metastatic breast cancer in different age groups [J]. Journal of Practical Oncology, 2019, 33(4): 352-356.
[10]	YAO Yang, ZHANG Yanqiao. Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors [J]. Journal of Practical Oncology, 2019, 33(4): 371-375.
[11]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[12]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[13]	HOU Yuxue,LI Xiaoli. The research progress of Wnt7a and malignant tumors,and its relationship [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 271-275.
[14]	ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.
[15]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.

The role of CA153 in breast cancer immunotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments